Cargando…

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer

Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braunstein, Lior Z., Chen, Ming-Hui, Loffredo, Marian, Kantoff, Philip W., D'Amico, Anthony V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016923/ https://www.ncbi.nlm.nih.gov/pubmed/24864213 http://dx.doi.org/10.1155/2014/230812

Ejemplares similares

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
por: D'Amico, Anthony V., et al.
Publicado: (2021)

Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy
por: WILSON, REBEKAH L., et al.
Publicado: (2021)

Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators
por: Martin, Neil E., et al.
Publicado: (2014)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Evidence Suggesting That Obesity Prevention Measures May Improve Prostate Cancer Outcomes Using Data from a Prospective Randomized Trial
por: Chandra, Ravi A., et al.
Publicado: (2014)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
por: Shah, Neil J, et al.
Publicado: (2022)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer
por: Gui, Bin, et al.
Publicado: (2017)

Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy
por: Saylor, Philip J., et al.
Publicado: (2009)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat
por: Mangiola, Stefano, et al.
Publicado: (2019)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation
por: Rosa-Ribeiro, Rafaela, et al.
Publicado: (2014)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
por: Qin, Caipeng, et al.
Publicado: (2022)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy
por: Cmero, Marek, et al.
Publicado: (2021)

Prepregnancy Body Mass Index, Gestational Weight Gain, and Odds of Cesarean Delivery in Hispanic Women
por: Harvey, Megan W., et al.
Publicado: (2017)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy
por: Blute, Michael L., et al.
Publicado: (2017)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e3emeaoar7s651al4vnft38ib6